American Journal of Hypertension最新文献

筛选
英文 中文
Ventricular-Arterial Coupling and Hypertension: Integrating Vascular and Cardiac Indices. 心室-动脉耦合与高血压:整合血管和心脏指标。
IF 3.1 3区 医学
American Journal of Hypertension Pub Date : 2025-08-04 DOI: 10.1093/ajh/hpaf147
Sepiso K Masenga
{"title":"Ventricular-Arterial Coupling and Hypertension: Integrating Vascular and Cardiac Indices.","authors":"Sepiso K Masenga","doi":"10.1093/ajh/hpaf147","DOIUrl":"https://doi.org/10.1093/ajh/hpaf147","url":null,"abstract":"","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144774517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Associations of Novel Triglyceride- and Triglyceride-Glucose-Derived Obesity Indices with Hypertension in Nonobese US Adults (NHANES 1999--2020). 新型甘油三酯和甘油三酯葡萄糖衍生的肥胖指数与非肥胖美国成年人高血压的关系(NHANES 1999- 2020)。
IF 3.1 3区 医学
American Journal of Hypertension Pub Date : 2025-08-01 DOI: 10.1093/ajh/hpaf146
Lingling Chen, Lixue Yin
{"title":"Associations of Novel Triglyceride- and Triglyceride-Glucose-Derived Obesity Indices with Hypertension in Nonobese US Adults (NHANES 1999--2020).","authors":"Lingling Chen, Lixue Yin","doi":"10.1093/ajh/hpaf146","DOIUrl":"https://doi.org/10.1093/ajh/hpaf146","url":null,"abstract":"<p><strong>Background: </strong>Visceral obesity, insulin resistance (IR), and glycolipid abnormalities are associated with an increased risk of hypertension (HTN). The study aimed to explore the correlation between novel triglyceride- and triglyceride‒glucose-derived obesity indices associated with these hypertension risk factors, and the prevalence of HTN among nonobese adults.</p><p><strong>Methods: </strong>We extracted data from 12,717 nonobese adults from NHANES between 1999-2020 and calculated triglyceride-derived obesity indices (lipid accumulation product (LAP), visceral adiposity index (VAI), and cardiometabolic index (CMI)), triglyceride-glucose-derived obesity indices (triglyceride glucose-body mass index (TyG-BMI), triglyceride glucose-waist circumference (TyG-WC), and triglyceride glucose-waist-to-height ratio (TyG-WHtR)) and traditional anthropometric indices. Logistic regression, curve fitting and subgroup analyses were employed to investigate the associations between these novel obesity indices and HTN prevalence. Receiver operating characteristic (ROC) curve analysis was performed to assess the predictive accuracy of all the above obesity parameters.</p><p><strong>Results: </strong>After weighted analysis of the data, the results of this study represented approximately 119.00 million nonobese U.S. adults. The prevalence of HTN was 49.74% (men 53.45%). The multivariate logistic regression analysis revealed that LAP, VAI, CMI, TyG-BMI, TyG-WC and TyG-WHtR were significantly associated with HTN. Smoothed curve-fitting analysis revealed that the LAP, VAI and CMI correlated nonlinearly with HTN.The area under the curve (AUC) for HTN was greater for all novel obesity indices compared to commonly used traditional anthropometric parameters such as BMI, WC, and WHtR.</p><p><strong>Conclusions: </strong>LAP, VAI, CMI, TyG-BMI, TyG-WC, and TyG-WHtR were significantly associated with HTN and demonstrated potentially better predictive capability than commonly used traditional anthropometric measures.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144758957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2017 ACC/AHA BP Thresholds for Masked HTN Detection. 2017 ACC/AHA BP阈值屏蔽HTN检测。
IF 3.1 3区 医学
American Journal of Hypertension Pub Date : 2025-07-26 DOI: 10.1093/ajh/hpaf123
Paul Anthony Camacho López, German Camilo Giraldo-Gonzalez, Silvia Juliana Villabona-Flórez, Alberto Javier Vasquez-Cadena
{"title":"2017 ACC/AHA BP Thresholds for Masked HTN Detection.","authors":"Paul Anthony Camacho López, German Camilo Giraldo-Gonzalez, Silvia Juliana Villabona-Flórez, Alberto Javier Vasquez-Cadena","doi":"10.1093/ajh/hpaf123","DOIUrl":"https://doi.org/10.1093/ajh/hpaf123","url":null,"abstract":"","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144726489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of sacubitril-valsartan on transcriptomic changes in lung tissue of spontaneously hypertensive rats: a multi-omics study based on RNA-Seq transcriptome analysis. 沙比替-缬沙坦对自发性高血压大鼠肺组织转录组变化的影响:基于RNA-Seq转录组分析的多组学研究。
IF 3.1 3区 医学
American Journal of Hypertension Pub Date : 2025-07-25 DOI: 10.1093/ajh/hpaf143
Zhengxiang Lv, Weiran Dai, Shunkang Rong, Jianlin Du
{"title":"Effect of sacubitril-valsartan on transcriptomic changes in lung tissue of spontaneously hypertensive rats: a multi-omics study based on RNA-Seq transcriptome analysis.","authors":"Zhengxiang Lv, Weiran Dai, Shunkang Rong, Jianlin Du","doi":"10.1093/ajh/hpaf143","DOIUrl":"https://doi.org/10.1093/ajh/hpaf143","url":null,"abstract":"<p><strong>Background: </strong>Hypertension, a prevalent cardiovascular disorder, exerts detrimental effects on the respiratory system. However, the underlying mechanisms remain incompletely elucidated.</p><p><strong>Methods: </strong>We conducted comparative transcriptomic profiling via RNA sequencing (RNA-seq) of lung tissues from spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto (WKY) controls. Additionally, we assessed the effects of angiotensin receptor blocker (ARB) and angiotensin receptor-neprilysin inhibitor (ARNI) interventions on mRNA and protein expression profiles in SHR pulmonary tissue using integrated omics approaches.</p><p><strong>Results: </strong>Core differentially expressed genes (DEGs) identified in SHR versus WKY comparisons included Nuf2 and Cenpa, with significant enrichment in the PI3K/AKT signaling pathway. In SHR versus ARB-treated cohorts, hub genes Ccnb2 and Mad2l1 demonstrated primary pathway enrichment in cell cycle regulation and human T-cell leukemia virus 1 infection. ARNI intervention yielded distinct hub genes (Gzma, Icam1) enriched in PI3K/AKT signaling and extracellular matrix (ECM)-receptor interactions. Proteomic analysis confirmed concordant expression patterns for EGFR and JUN proteins with transcriptomic findings.</p><p><strong>Conclusion: </strong>ARB and ARNI therapies mitigate hypertension-induced pulmonary damage through divergent molecular mechanisms, with PI3K/AKT signaling and ECM-receptor interactions serving as central regulatory hubs in this protective process.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144726490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Soluble Receptor for Advanced Glycation End Products and Incident Hypertension in REGARDS. 晚期糖基化终产物的可溶性受体和REGARDS中的高血压事件。
IF 3.2 3区 医学
American Journal of Hypertension Pub Date : 2025-07-25 DOI: 10.1093/ajh/hpaf109
Sarah D R Krumholz, Mary Cushman, Nels C Olson, D Leann Long, Suzanne E Judd, Virginia J Howard, Timothy B Plante
{"title":"Soluble Receptor for Advanced Glycation End Products and Incident Hypertension in REGARDS.","authors":"Sarah D R Krumholz, Mary Cushman, Nels C Olson, D Leann Long, Suzanne E Judd, Virginia J Howard, Timothy B Plante","doi":"10.1093/ajh/hpaf109","DOIUrl":"https://doi.org/10.1093/ajh/hpaf109","url":null,"abstract":"<p><strong>Background: </strong>Black US adults experience a greater hypertension burden and have lower levels of soluble receptors for advanced glycation end products (sRAGE). sRAGE may reduce inflammation, which is itself a hypertension risk factor. We hypothesized that higher sRAGE levels are associated with a lower risk of incident hypertension in a cohort of Black and White adults.</p><p><strong>Methods: </strong>The REasons for Geographic and Racial Differences in Stroke (REGARDS) enrolled 30,239 Black and White adults from the contiguous United States in 2003-2007; a second visit occurred in 2013-2016. sRAGE was measured at baseline by ELISA in 4,400 participants attending both visits. Hypertension was defined as BP > 140/90 mm Hg or use of antihypertensive medications. Participants with baseline hypertension were excluded. Poisson regression estimated incident hypertension risk ratios (RR) by sRAGE levels, adjusting for confounders.</p><p><strong>Results: </strong>Among 1,799 participants without baseline hypertension (mean [SD] age 62 [8] years, 55% females, 25% Black), 46% of Black participants and 31% of White participants developed hypertension. Median sRAGE was lower in Black than White persons (P < 0.0001). Relative to quartile 1, White participants in quartile 4 of sRAGE had a 24% lower risk of incident hypertension (RR 0.76; 95% CI 0.59, 0.96) in a minimally adjusted model, but no differences in a fully adjusted model (0.81; 0.63 to 1.05). There was no association of sRAGE with hypertension in Black participants.</p><p><strong>Conclusions: </strong>Higher baseline sRAGE levels were not associated with lower risk of incident hypertension after adjusting for known confounders. Low sRAGE might represent adverse inflammation that drives hypertension rather than being a primary driver of hypertension development itself.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of SGLT2 inhibitors on blood pressure in relation to baseline kidney function: A systematic literature review and data analysis. SGLT2抑制剂对血压和基线肾功能的影响:系统的文献回顾和数据分析。
IF 3.1 3区 医学
American Journal of Hypertension Pub Date : 2025-07-24 DOI: 10.1093/ajh/hpaf130
Charlotte Agergaard Møller, Steffen Flindt Nielsen, Frank Holden Mose
{"title":"The effect of SGLT2 inhibitors on blood pressure in relation to baseline kidney function: A systematic literature review and data analysis.","authors":"Charlotte Agergaard Møller, Steffen Flindt Nielsen, Frank Holden Mose","doi":"10.1093/ajh/hpaf130","DOIUrl":"https://doi.org/10.1093/ajh/hpaf130","url":null,"abstract":"<p><strong>Background: </strong>Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce both systolic blood pressure (SBP) and diastolic blood pressure (DBP). The glucose-lowering effect of SGLT2i depends on baseline estimated glomerular filtration rate (eGFR), but whether the same is true for the blood pressure lowering effect is unknown.</p><p><strong>Methods: </strong>We performed a systematic literature review in PubMed (Study 1) and analysed data from a clinical study (Study 2) to investigate if the blood pressure lowering effect of SGLT2i depends on baseline eGFR. In the literature review, we performed a weighted regression analysis with mean change in SBP and DBP as dependent variables and mean eGFR as an independent variable. Furthermore, we analyzed data from a cohort of 48 patients with either type 2 diabtes mellitus with and without chronic kidney disease (CKD) or non-diabetic CKD with varying degrees of kidney function.</p><p><strong>Results: </strong>2069 articles were identified of which 27 articles met the inclusion criteria. Analysis revealed a mean weighted reduction in SBP -4.7 mmHg compared to baseline and -3.5 mmHg compared to placebo. The weighted regression analysis showed no correlation between change in SBP and baseline eGFR. Data analysis of 48 patients revealed a SBP reduction of 5.5 mmHg and the simple linear regression revealed no correlation between the decrease in blood pressure and baseline eGFR.</p><p><strong>Conclusions: </strong>The blood pressure lowering effect of SGLT2i does not depend on baseline eGFR.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144726492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact of Time in Target Range for Systolic Blood Pressure on Left Ventricular Hypertrophy. 收缩压目标范围时间对左室肥厚的影响。
IF 3.1 3区 医学
American Journal of Hypertension Pub Date : 2025-07-24 DOI: 10.1093/ajh/hpaf141
Jianjiao Wang, Wen Li, Gui Man, Yang Liu, Siyu Wang, Shouling Wu, Wei Huang
{"title":"The Impact of Time in Target Range for Systolic Blood Pressure on Left Ventricular Hypertrophy.","authors":"Jianjiao Wang, Wen Li, Gui Man, Yang Liu, Siyu Wang, Shouling Wu, Wei Huang","doi":"10.1093/ajh/hpaf141","DOIUrl":"https://doi.org/10.1093/ajh/hpaf141","url":null,"abstract":"<p><strong>Background: </strong>We aimed to explore the association between systolic blood pressure time-in-target range (SBP-TTR) and left ventricular hypertrophy (LVH).</p><p><strong>Methods: </strong>A total of 33,818 participants of the Kailuan Study who underwent echocardiography and had participated in at least two health check-ups between 2006 and 2020. The target systolic blood pressure (SBP) ranges are defined as 120-140 mmHg and 110-130 mmHg, respectively. SBP-TTR was calculated by linear interpolation. Poisson regression models were used to assess relative risk (RR) and 95% confidence intervals (CIs) for the associations of 120-140 mmHg SBP-TTR and 110-130 mmHg SBP-TTR with LVH.</p><p><strong>Results: </strong>When the SBP target range was defined as 120-140mmHg, in multivariable-adjusted models, compared to the reference group (SBP-TTR ≤ 25%), LVH risk was significantly reduced in the 75% < SBP-TTR ≤ 100% group, (RR: 0.94, 95% CI: 0.89-0.99). When the SBP target range was defined as 110-130mmHg, compared to the reference group (SBP-TTR ≤ 25%),there was significantly reduced in LVH risk in the 25%<SBP-TTR≤50%(RR:0.89,95%CI:0.83-0.94)、50%<SBP-TTR≤75%(RR:0.85,95%CI:0.79-0.91) and 75%< SBP-TTR≤100%(RR:0.81,95%CI:0.76-0.86)groups. Analysis using restricted cubic splines revealed a linear, dose-response relationship between SBP-TTR and LVH risk.</p><p><strong>Conclusions: </strong>With increased SBP-TTR associated with a reduced risk of LVH, demonstrating a clear dose-response relationship. Compared to an SBP-TTR range of 120-140 mmHg, maintaining SBP-TTR at 110-130 mmHg more effectively reduces LVH risk.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144726493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intensive Blood Pressure Control in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Cardiovascular and Microvascular Outcomes. 2型糖尿病强化血压控制:心血管和微血管结局的系统回顾和荟萃分析
IF 3.1 3区 医学
American Journal of Hypertension Pub Date : 2025-07-24 DOI: 10.1093/ajh/hpaf140
Asma Mousavi, Shayan Shojaei, Amir Parsa Abhari, Seyed Alireza Mirhosseini, Rasoul Ebrahimi, Erta Rajabi, Mashood Ahmad Farooqi, Amirali Azizpour, Shiva Armani Moghadam, Toshiki Kuno, Anil Harrison, Wilbert Aronow, Abdul Waheed, Rosy Thachil, Kaveh Hosseini
{"title":"Intensive Blood Pressure Control in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Cardiovascular and Microvascular Outcomes.","authors":"Asma Mousavi, Shayan Shojaei, Amir Parsa Abhari, Seyed Alireza Mirhosseini, Rasoul Ebrahimi, Erta Rajabi, Mashood Ahmad Farooqi, Amirali Azizpour, Shiva Armani Moghadam, Toshiki Kuno, Anil Harrison, Wilbert Aronow, Abdul Waheed, Rosy Thachil, Kaveh Hosseini","doi":"10.1093/ajh/hpaf140","DOIUrl":"https://doi.org/10.1093/ajh/hpaf140","url":null,"abstract":"<p><strong>Background: </strong>The optimal blood pressure (BP) target for adults with type 2 diabetes (T2DM) remains a topic of debate. This systematic review and meta-analysis aimed to investigate the efficacy of intensive BP control strategies compared to standard or less intensive approaches in adults with T2DM.</p><p><strong>Method: </strong>We comprehensively searched databases for studies comparing intensive versus less intensive BP targets in individuals with T2DM. In this study, the group with the most intensive target was compared to the group with the least intensive target. Also, studies were analyzed based on current guideline recommendations. Outcomes of interest included major adverse cardiovascular events (MACE), all-cause mortality, cardiovascular mortality, myocardial infarction (MI), stroke, heart failure, retinopathy, neuropathy, nephropathy, and end-stage renal disease. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated.</p><p><strong>Results: </strong>The meta-analysis included 21 studies (16 RCTs) with 290,907 participants (mean age 61.84 years, 55.03% male). Guideline-based analyses showed comparable clinical outcomes between groups with no significant differences. However, the most intensive targets vs. the least intensive targets revealed that the intensive BP control group experienced a significantly lower risk of MACE (RR=0.75, 0.58; 0.98), non-fatal myocardial infarction (RR=0.61, 0.41; 0.91), non-fatal stroke (RR=0.60, 0.39; 0.92), and total stroke (RR=0.61, 0.39; 0.95). Other outcomes were similar between groups. Subgroup analysis of RCTs mirrored the overall findings.</p><p><strong>Conclusion: </strong>In adults with T2DM, intensive BP control reduces the risk of cardiovascular events, such as MACE, stroke, and MI. Additionally, it demonstrates comparable diabetes-related complications to less intensive or standard controls.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144726491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Renal Denervation to Treat Hypertension: A Clinical State-of-the-Art Review. 肾去神经治疗高血压:一项最新的临床研究综述。
IF 3.2 3区 医学
American Journal of Hypertension Pub Date : 2025-07-23 DOI: 10.1093/ajh/hpaf134
Andrew S P Sharp, Naomi D L Fisher
{"title":"Renal Denervation to Treat Hypertension: A Clinical State-of-the-Art Review.","authors":"Andrew S P Sharp, Naomi D L Fisher","doi":"10.1093/ajh/hpaf134","DOIUrl":"https://doi.org/10.1093/ajh/hpaf134","url":null,"abstract":"<p><p>Hypertension represents the leading risk factor for death globally, affecting one in two adults. Despite dozens of inexpensive medications and lifestyle changes that effectively lower blood pressure, hypertension control rates remain poor. Renal denervation (RDN) is a procedural therapy indicated as an adjunctive treatment for high blood pressure. FDA approval in late 2023 followed the publication of a series of rigorous, second-generation, randomized clinical trials that demonstrated safety and efficacy of the procedure. Two catheters employing radiofrequency (Spyral) and ultrasound (Paradise) are currently approved to ablate renal sympathetic nerves. In randomized sham-controlled trials, RDN lowered blood pressure in patients with mild-to-moderate and true resistant hypertension, and in patients both on and off anti-hypertensive medication. When evaluating patients for RDN, shared decision-making is a critical element, which should include potential benefits and that a minority may not respond to the therapy. There is only one constant predictor of magnitude of response: magnitude of baseline SBP, which is one reason why guidelines recommend prioritization of patients with resistant hypertension, together with patients whose BP cannot be effectively managed with medication. Before referring patients to a trained interventionalist, it is important to optimize medical therapy and adherence, and confirm uncontrolled hypertension out-of-office. Patients should be screened for primary aldosteronism and for other secondary causes of hypertension if clinically indicated, though sleep apnea is not a contraindication to RDN. A team approach is advised, with hypertension specialists and interventionalists collaborating. Data from global registries will augment our knowledge and guide future implementation.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic Impact of Different Definitions of White-Coat Hypertension. 不同白大褂高血压定义对预后的影响。
IF 3.2 3区 医学
American Journal of Hypertension Pub Date : 2025-07-23 DOI: 10.1093/ajh/hpaf136
Paolo Verdecchia, Stefano Coiro, Claudia Bartolini, Adolfo Aita, Claudia Borgioni, Salvatore Repaci, Chiara Dembech, Massimo Guerrieri, Nicola Sacchi, Sergio Bistoni, Mario Trottini, Fabio Angeli
{"title":"Prognostic Impact of Different Definitions of White-Coat Hypertension.","authors":"Paolo Verdecchia, Stefano Coiro, Claudia Bartolini, Adolfo Aita, Claudia Borgioni, Salvatore Repaci, Chiara Dembech, Massimo Guerrieri, Nicola Sacchi, Sergio Bistoni, Mario Trottini, Fabio Angeli","doi":"10.1093/ajh/hpaf136","DOIUrl":"https://doi.org/10.1093/ajh/hpaf136","url":null,"abstract":"<p><strong>Background: </strong>Different definitions of white-coat hypertension (WCH) may explain its variable outcome across studies.</p><p><strong>Methods: </strong>In an Italian study started in year 1986, we followed 3,153 people with (office blood pressure (BP) >=140/90 mmHg) and 457 without office hypertension for a mean of 10.4 years. None had previous cardiovascular disease. All underwent 24-hour ambulatory BP (ABP) monitoring. We defined WCH as an average 24-hour ABP <130/80 mmHg or <125/75 mmHg. Primary outcome was a composite of major adverse cardiovascular events (MACE), and all-cause mortality.</p><p><strong>Results: </strong>Baseline office BP was 156/97 mmHg in people with and 127/81 mmHg without hypertension. At follow-up, MACE events were 344 and 23, and all-cause deaths 318 and 24 in people with and without hypertension, respectively. Compared to normotensive group, MACE risk was not higher in people with WCH and 24-hour ABP <125/75 mmHg (hazard ratio (HR), 0.94; 95% confidence interval (CI), 0.42-2.10). Compared to normotensive group, MACE risk was higher in people with WCH and 24-hour ABP <130/80 mmHg (HR: 1.79; 95% CI: 1.07-2.29). All-cause death did not differ between the normotensive group and people with WCH and 24-hour ABP <125/75 mmHg (HR 1.37; 95% CI 0.68-2.73), but it was higher than in the normotensive group when WCH was defined by a 24-hour ABP <130/80 mmHg (HR 1.82; 95% CI 1.55-3.58).</p><p><strong>Conclusions: </strong>WCH defined by an average 24-hour ABP <125/75 mmHg identifies people at low risk of MACE and death in the long-term. Even modestly above these threshold values, the risk associated with WCH increases.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信